$ABL
Abacus Life, Inc. Stock $abl

$abl Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000181428724000028 Filed on March 21, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$21.49M	$23.70M	$66.40M
YoY Change
Cost Of Revenue	$2.721M	$1.662M	$6.490M
YoY Change	455.29%		3.85%
Gross Profit	$18.77M	$22.03M	$59.91M
YoY Change	91.88%		55.73%
Gross Profit Margin	87.34%	92.98%	90.23%
Selling, General & Admin	$13.28M	$17.16M	$31.39M
YoY Change	828.91%		757.6%
% of Gross Profit	70.78%	77.87%	52.39%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.682M	$1.710M	$3.410M
YoY Change
% of Gross Profit	8.96%	7.76%	5.69%
Operating Expenses	$16.51M	$20.92M	$35.79M
YoY Change	1148.08%	866.84%	205.27%
Operating Profit	$2.253M	$1.116M	$24.13M
YoY Change	-73.36%		-9.8%
Interest Expense	$3.670M	-$2.759M	$9.867M
YoY Change	211.23%	203.67%	-7.07%
% of Operating Profit	162.9%	-247.18%	40.9%
Other Income/Expense, Net	-$2.355M	-$3.406M	-$13.62M
YoY Change	-299.7%	-763.66%	-222.38%
Pretax Income	-$102.0K	-$7.135M	$10.50M
YoY Change	-29.07%	178.85%	-1876.92%
Income Tax	$1.174M	-$769.9K	$1.469M
% Of Pretax Income			13.98%
Net Earnings	-$1.349M	-$6.222M	$9.517M
YoY Change	838.28%	144.36%	-1578.74%
Net Earnings / Revenue	-6.28%	-26.26%	14.33%
Basic Earnings Per Share	-$0.02		$0.17
Diluted Earnings Per Share	-$0.02	-$0.10	$0.16
COMMON SHARES
Basic Shares Outstanding	63.69M shares	63.35M shares	56.95M shares
Diluted Shares Outstanding	63.03M shares		57.77M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$68.79M	$27.84M	$27.84M
YoY Change	120733.32%	32060.75%	32060.75%
Cash & Equivalents	$65.39M	$25.59M	$25.59M
Short-Term Investments	$3.404M	$2.253M	$2.253M
Other Short-Term Assets	$2.038M	$699.1K	$699.1K
YoY Change	1048.35%	977.08%	977.08%
Inventory
Prepaid Expenses
Receivables	$3.496M	$3.236M	$3.236M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$74.32M	$31.78M	$31.78M
YoY Change	31610.27%	20876.75%	20876.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$547.6K	$400.7K	$2.294M
YoY Change	447.56%	2052.44%	2194.38%
Goodwill	$140.3M	$140.3M
YoY Change
Intangibles	$28.05M	$29.62M
YoY Change
Long-Term Investments	$129.8M	$126.8M	$126.8M
YoY Change	341.81%	27.84%	27.84%
Other Assets	$1.501M	$999.0K	$999.0K
YoY Change	36.46%	12.14%	12.24%
Total Long-Term Assets	$302.4M	$300.0M	$300.0M
YoY Change	929.07%	202.4%	202.4%
TOTAL ASSETS
Total Short-Term Assets	$74.32M	$31.78M	$31.78M
Total Long-Term Assets	$302.4M	$300.0M	$300.0M
Total Assets	$376.7M	$331.8M	$331.8M
YoY Change	1171.85%	233.92%	233.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Accrued Expenses	$707.2K	$4.354M	$4.472M
YoY Change	-92.98%	-52.81%	-51.53%
Deferred Revenue	$667.5K	$507.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$15.65M	$13.03M	$13.03M
YoY Change
Total Short-Term Liabilities	$23.84M	$23.33M	$23.33M
YoY Change	45.32%	24.2%	24.2%
LONG-TERM LIABILITIES
Long-Term Debt	$170.2M	$126.8M	$126.8M
YoY Change
Other Long-Term Liabilities	$7.725M	$8.440M	$8.440M
YoY Change	127.24%
Total Long-Term Liabilities	$177.9M	$135.2M	$135.2M
YoY Change	5132.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.84M	$23.33M	$23.33M
Total Long-Term Liabilities	$177.9M	$135.2M	$135.2M
Total Liabilities	$211.4M	$167.8M	$167.9M
YoY Change	967.5%	793.24%	793.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$36.07M	-$34.73M
YoY Change	84.84%	88.58%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$165.1M	$163.9M	$163.9M
YoY Change
Total Liabilities & Shareholders Equity	$376.7M	$331.8M	$331.8M
YoY Change	1171.85%	233.92%	233.92%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.349M	-$6.222M	$9.517M
YoY Change	838.28%	144.36%	-1578.74%
Depreciation, Depletion And Amortization	$1.682M	$1.710M	$3.410M
YoY Change
Cash From Operating Activities	$2.267M	-$13.34M	-$64.52M
YoY Change	-553.09%	2031.12%	2379.48%
INVESTING ACTIVITIES
Capital Expenditures	$161.8K	$89.67K	$189.7K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$247.2K	-$238.8K	$2.431M
YoY Change	-99.65%	-75.18%	-99.01%
Cash From Investing Activities	-$6.629K	-$328.5K	$2.242M
YoY Change	-100.01%	-65.86%	-99.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.283M
YoY Change
Debt Paid & Issued, Net			$26.25M
YoY Change
Cash From Financing Activities	$37.54M	2.617M	$57.82M
YoY Change	-154.11%		-123.63%
NET CHANGE
Cash From Operating Activities	$2.267M	-13.34M	-$64.52M
Cash From Investing Activities	-$6.629K	-328.5K	$2.242M
Cash From Financing Activities	$37.54M	2.617M	$57.82M
Net Change In Cash	$39.80M	-11.05M	-$4.464M
YoY Change	-134375.26%	595.98%	482.36%
FREE CASH FLOW
Cash From Operating Activities	$2.267M	-$13.34M	-$64.52M
Capital Expenditures	$161.8K	$89.67K	$189.7K
Free Cash Flow	$2.105M	-$13.43M	-$64.71M
YoY Change	-520.76%	2045.44%	2386.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3409928	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	1369112	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1045623	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001814287
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Other Comprehensive Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39403
CY2023	dei	Entity Registrant Name EntityRegistrantName	Abacus Life, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1210472
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2101 Park Center Drive, Suite 200
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Orlando
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32835
CY2023	dei	City Area Code CityAreaCode	800
CY2023	dei	Local Phone Number LocalPhoneNumber	561-4148
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	11651731	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	63694758	shares
CY2023	dei	Auditor Firm AuditorFirmId	248
CY2023	dei	Auditor Name AuditorName	GRANT THORNTON LLP
CY2023	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25588668	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30052823	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	2252891	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	0	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	699127	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	116646	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	31776834	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	33282927	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	400720	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18617	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	29623130	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	usd
CY2023Q4	us-gaap	Goodwill Goodwill	140287000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1893659	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	77011	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1697178	usd
CY2022Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	8716111	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	122296559	usd
CY2022Q4	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	13809352	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	1105935	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	1000000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1650000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1300000	usd
CY2023Q4	us-gaap	Other Receivable After Allowance For Credit Loss Noncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent	998945	usd
CY2022Q4	us-gaap	Other Receivable After Allowance For Credit Loss Noncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent	0	usd
CY2023Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	96107	usd
CY2022Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	890829	usd
CY2023Q4	us-gaap	Assets Assets	331826067	usd
CY2022Q4	us-gaap	Assets Assets	59094847	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	13029632	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4354225	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	0	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	0	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	40014	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	118058	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	48127	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	507000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2023Q4	abl	Accrued Transaction Costs Current AccruedTransactionCostsCurrent	0	usd
CY2022Q4	abl	Accrued Transaction Costs Current AccruedTransactionCostsCurrent	908256	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	751734	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23326331	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1302409	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1796727	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29268	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	9199091	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1363820	usd
CY2023Q4	abl	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	6642960	usd
CY2022Q4	abl	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	167755991	usd
CY2022Q4	us-gaap	Liabilities Liabilities	30945150	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	146650	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1283062	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	0	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	704963	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-34726135	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	199826278	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	25487323	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	108373	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1052836	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	138283	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	899538	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	164070076	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28149697	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	331826067	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59094847	usd
CY2023	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	17980987	usd
CY2022	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	37828829	usd
CY2023	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	43214390	usd
CY2022	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	5413751	usd
CY2023	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	61195377	usd
CY2022	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	43242580	usd
CY2023	us-gaap	Revenues Revenues	66401451	usd
CY2022	us-gaap	Revenues Revenues	44713552	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	5884669	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26482571	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-2356058	usd
CY2022	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-90719	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4282	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	35785192	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	5163629	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	24125882	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	33665254	usd
CY2023	abl	Gain Loss On Change In Fair Value Of Warrant Liability GainLossOnChangeInFairValueOfWarrantLiability	-4204360	usd
CY2022	abl	Gain Loss On Change In Fair Value Of Warrant Liability GainLossOnChangeInFairValueOfWarrantLiability	0	usd
CY2023	us-gaap	Interest Expense InterestExpense	9866821	usd
CY2022	us-gaap	Interest Expense InterestExpense	42798	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	594764	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1474	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-146443	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-347013	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13622860	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-388337	usd
CY2023	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	10503022	usd
CY2022	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	33276917	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1468535	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	889943	usd
CY2023	us-gaap	Profit Loss ProfitLoss	9034487	usd
CY2022	us-gaap	Profit Loss ProfitLoss	32386974	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-482139	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	704699	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	9516626	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	31682275	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.17
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.63
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56951414	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50369350	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57767898	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50369350	shares
CY2023	us-gaap	Profit Loss ProfitLoss	9034487	usd
CY2023	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	-1248330	usd
CY2022	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	1395830	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	7786157	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	33782804	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-800311	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1047693	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	8586468	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	32735111	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	766893	usd
CY2022	us-gaap	Dividends Dividends	6400000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1395830	usd
CY2022	us-gaap	Profit Loss ProfitLoss	32386974	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28149697	usd
CY2023	us-gaap	Dividends Dividends	34451607	usd
CY2023	abl	Stockholders Equity Deferred Transaction Costs StockholdersEquityDeferredTransactionCosts	11397402	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	960900	usd
CY2023	abl	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	-2796225	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	165361332	usd
CY2023	abl	Adjustments To Additional Paid In Capital Increase From Spac Trust Proceeds AdjustmentsToAdditionalPaidInCapitalIncreaseFromSPACTrustProceeds	972262	usd
CY2023	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1283062	usd
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	39000	shares
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10768024	usd
CY2023	abl	Noncontrolling Interest Increase From Transfer Of Noncontrolling Interest NoncontrollingInterestIncreaseFromTransferOfNoncontrollingInterest	0	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1248330	usd
CY2023	us-gaap	Profit Loss ProfitLoss	9034487	usd
CY2023	us-gaap	Profit Loss ProfitLoss	9034487	usd
CY2022	us-gaap	Profit Loss ProfitLoss	32386974	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3409928	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4282	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	10768024	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	43957	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2086303	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4204360	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	1369112	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1045623	usd
CY2023	us-gaap	Life Settlement Contracts Fair Value Method Unrealized Gain Loss LifeSettlementContractsFairValueMethodUnrealizedGainLoss	27889106	usd
CY2022	us-gaap	Life Settlement Contracts Fair Value Method Unrealized Gain Loss LifeSettlementContractsFairValueMethodUnrealizedGainLoss	5742377	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-2356058	usd
CY2022	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-90719	usd
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	466577	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	889943	usd
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest	2182221	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
CY2023	abl	Operating Lease Right Of Use Asset Noncash Income Expense OperatingLeaseRightOfUseAssetNoncashIncomeExpense	-17901	usd
CY2022	abl	Operating Lease Right Of Use Asset Noncash Income Expense OperatingLeaseRightOfUseAssetNoncashIncomeExpense	-383	usd
CY2023	us-gaap	Other Noncash Income OtherNoncashIncome	105935	usd
CY2022	us-gaap	Other Noncash Income OtherNoncashIncome	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2117411	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10448	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-124565	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	130873	usd
CY2023	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	89057	usd
CY2022	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	0	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	62994	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	91741	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	522326	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1936452	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-40014	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	40014	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3829825	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	usd
CY2023	abl	Increase Decrease In Accrued Transaction Costs IncreaseDecreaseInAccruedTransactionCosts	-908256	usd
CY2022	abl	Increase Decrease In Accrued Transaction Costs IncreaseDecreaseInAccruedTransactionCosts	908256	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-474217	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	3358507	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	22037	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	751734	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
CY2023	abl	Life Settlement Contract Purchased Fair Value Method LifeSettlementContractPurchasedFairValueMethod	80598101	usd
CY2022	abl	Life Settlement Contract Purchased Fair Value Method LifeSettlementContractPurchasedFairValueMethod	8066975	usd
CY2023	abl	Life Settlement Contract Purchased Investment Method LifeSettlementContractPurchasedInvestmentMethod	-7018933	usd
CY2022	abl	Life Settlement Contract Purchased Investment Method LifeSettlementContractPurchasedInvestmentMethod	8716111	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-64523149	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10693254	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	189674	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	350000	usd
CY2022	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	50000	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	750000	usd
CY2023	abl	Proceeds Due From Payments Due To Affiliates ProceedsDueFromPaymentsDueToAffiliates	2781176	usd
CY2022	abl	Proceeds Due From Payments Due To Affiliates ProceedsDueFromPaymentsDueToAffiliates	-2904646	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2241502	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3704646	usd
CY2023	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	442283	usd
CY2022	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	5547943	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	26250000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2023	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	11397402	usd
CY2022	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	0	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1283062	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023	abl	Proceeds Received From Spac Trust ProceedsReceivedFromSPACTrust	972262	usd
CY2022	abl	Proceeds Received From Spac Trust ProceedsReceivedFromSPACTrust	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	57817492	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22961795	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4464155	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29950403	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30052823	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102420	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25588668	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30052823	usd
CY2023	abl	Life Settlement Contracts Obtained In Exchange For Long Term Debt LifeSettlementContractsObtainedInExchangeForLongTermDebt	10191125	usd
CY2022	abl	Life Settlement Contracts Obtained In Exchange For Long Term Debt LifeSettlementContractsObtainedInExchangeForLongTermDebt	0	usd
CY2023	abl	Life Settlement Contracts Distributions To Affliates LifeSettlementContractsDistributionsToAffliates	10191125	usd
CY2022	abl	Life Settlement Contracts Distributions To Affliates LifeSettlementContractsDistributionsToAffliates	0	usd
CY2023	abl	Capital Distribution Payable CapitalDistributionPayable	717429	usd
CY2022	abl	Capital Distribution Payable CapitalDistributionPayable	0	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	4035526	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	150000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14pt">DESCRIPTION OF BUSINESS</span><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Organization and Merger</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Abacus Life, Inc. (the “Company”) was formerly known as East Resources Acquisition Company ("ERES”), a blank check company incorporated in Delaware on May 22, 2020. Abacus Life, Inc. conducts its business through its wholly-owned, consolidated subsidiaries, primarily Abacus Settlements, LLC (“Abacus Settlements”, or “Abacus”) and Longevity Market Assets, LLC (“LMA”), which are Delaware limited liability companies (collectively, the “Companies”). On June 30, 2023, (the “Closing Date”), ERES, LMA and Abacus consummated the combining of the Companies as contemplated by the Merger Agreement dated as of August 30, 2022 (as amended on October 14, 2022 and April 20, 2023) with LMA Merger Sub, LLC, a wholly owned subsidiary of ERES (“LMA Merger Sub”), Abacus Merger Sub, LLC, a wholly owned subsidiary of ERES (“Abacus Merger Sub”), LMA and Abacus (together with LMA, the “Legacy Companies”). Pursuant to the Merger Agreement, on June 30, 2023, (i) LMA Merger Sub merged with and into LMA, with LMA surviving such merger (the “LMA Merger”) and (ii) Abacus Merger Sub merged with and into Abacus, with Abacus surviving such merger (the “Abacus Merger” and, together with the LMA Merger, the “Mergers” and, along with the other transactions contemplated by the Merger Agreement, the “Business Combination”) and the Legacy Companies became direct wholly owned subsidiaries of the Company. On the Closing Date, ERES changed its name to Abacus Life, Inc. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The consolidated assets, liabilities and statements of operations and comprehensive income prior to the Business Combination are those of legacy LMA. The shares of common stock and corresponding capital amounts and income per share, prior to the Business Combination, have been retroactively restated based on share reflecting the exchange ratio established in the Business Combination. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The equity structure has been recast in all comparative periods up to the Closing Date to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to legacy LMA’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and income per share related to legacy LMA common stock prior to the Business Combination have been retroactively recast as shares reflecting the exchange ratio of 0.8 established in the Business Combination.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Activity</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company, through its LMA subsidiary, is a provider of services pertaining to life insurance settlements and offers policy servicing to owners and purchasers of life settlement assets, as well as consulting, valuation, and actuarial services. The Company is also engaged in buying and selling of life settlement policies in which it uses its own capital, and purchases life settlement contracts with the intent to either hold to maturity to receive the associated death claim payout or to sell to another purchaser of life settlement contracts for a gain on the sale.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company, through its Abacus subsidiary, also is an originator of outstanding life insurance policies as a licensed life settlement provider on behalf of investors (“Financing Entities”). Abacus locates and screens policies for eligibility as a commercially desirable life settlement, including verifying that the policy is in force, obtaining consents and disclosures, and submitting cases for life expectancy estimates, also known, collectively, as origination services. When the sale of a policy is completed, this is deemed “settled” and the policy is then referred to as either a “life settlement” in which the insured’s life expectancy is greater than two years or “viatical settlement,” in which the insured’s life expectancy is less than two years. The Company is not an insurance company, and therefore the Company does not underwrite insurable risks for its own account.</span></div>
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	abl	Number Of Unaffiliated Investors Involved In Variable Interest Entity Ownership NumberOfUnaffiliatedInvestorsInvolvedInVariableInterestEntityOwnership	3	investor
CY2021Q4	abl	Number Of Unaffiliated Investors Involved In Variable Interest Entity Ownership NumberOfUnaffiliatedInvestorsInvolvedInVariableInterestEntityOwnership	3	investor
CY2021Q1	abl	Number Of Providers Involved In Option Agreement NumberOfProvidersInvolvedInOptionAgreement	2	provider
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The preparation of U.S. GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, disclosure of contingent assets and liabilities at the date of financial statements, and the reported amounts of revenue and expenses during the reporting periods. Company’s estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from the estimates. Estimates are used when accounting for purchase price allocation, the selection of useful lives of property and equipment, valuation of other receivables, valuation of life settlement policies, valuation of other investments and available-for-sale securities, valuation of long-term debt, impairment testing, income taxes, and legal reserves.</span></div>
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	105935	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	507000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2023	abl	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	507000	usd
CY2022	abl	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	0	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	507000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentrations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, accounts receivable, and available-for-sale securities. The Company maintains its cash in bank deposit accounts with high-quality financial institutions, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on its cash and cash equivalents. For accounts receivable, the Company is exposed to credit risk in the event of nonpayment by customers to the extent of the amounts recorded on the accompanying condensed consolidated balance sheets. The Company extends different levels of credit to its customers and maintains allowance for doubtful accounts based upon the expected collectability of accounts receivable. The Company’s procedures for determining this allowance includes evaluating individual customer receivables, considering a customer’s financial condition, monitoring credit history and current economic conditions, using historical experience applied to an aging of accounts, as well as management’s expectations of conditions in the future, as applicable.</span></div>
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2022Q4	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	35	insurance_contract
CY2022Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	18	insurance_contract
CY2022Q4	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	40092154	usd
CY2022Q4	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	13809352	usd
CY2022Q4	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	42330000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Certain prior period amounts have been reclassified to conform to current</span></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">presentation.</span></div>
CY2023Q4	abl	Life Settlement Contracts Number Of Contracts LifeSettlementContractsNumberOfContracts	296	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	287	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	9	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	520503710	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	122296559	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	33900000	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1697178	usd
CY2022Q4	abl	Life Settlement Contracts Number Of Contracts LifeSettlementContractsNumberOfContracts	53	insurance_contract
CY2022Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	8716111	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Next Twelve Months LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInNextTwelveMonths	2	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Next Twelve Months LifeSettlementContractsFairValueMethodFaceValueMaturingInNextTwelveMonths	383461	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Maturing In Next Twelve Months LifeSettlementContractsFairValueMaturingInNextTwelveMonths	315248	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Two LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearTwo	6	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Two LifeSettlementContractsFairValueMethodFaceValueMaturingInYearTwo	4391193	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Two LifeSettlementContractsFairValueMaturingInYearTwo	1590513	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Three LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearThree	13	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Three LifeSettlementContractsFairValueMethodFaceValueMaturingInYearThree	20692550	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Three LifeSettlementContractsFairValueMaturingInYearThree	10850243	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Four LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearFour	41	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Four LifeSettlementContractsFairValueMethodFaceValueMaturingInYearFour	66017222	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Four LifeSettlementContractsFairValueMaturingInYearFour	22744161	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Five LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearFive	29	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Five LifeSettlementContractsFairValueMethodFaceValueMaturingInYearFive	57814969	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Five LifeSettlementContractsFairValueMaturingInYearFive	19326245	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing After Year Five LifeSettlementContractsFairValueMethodNumberOfContractsMaturingAfterYearFive	196	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing After Year Five LifeSettlementContractsFairValueMethodFaceValueMaturingAfterYearFive	371204315	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Maturing After Year Five LifeSettlementContractsFairValueMaturingAfterYearFive	67470149	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	287	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	520503710	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	122296559	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInNextTwelveMonths	0	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodFaceValueMaturingInNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Two LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearTwo	1	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Two LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearTwo	500000	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Two LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearTwo	329714	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Three LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearThree	2	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Three LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearThree	1500000	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Three LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearThree	443544	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Four LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFour	1	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Four LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFour	8000000	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Four LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearFour	84199	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Five LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFive	2	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Five LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFive	500000	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Five LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearFive	320110	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing After Year Five LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingAfterYearFive	3	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing After Year Five LifeSettlementContractsInvestmentMethodFaceValueMaturingAfterYearFive	23400000	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing After Year Five LifeSettlementContractsInvestmentMethodCarryingAmountMaturingAfterYearFive	519611	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	9	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	33900000	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1697178	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Next Twelve Months LifeSettlementContractsInvestmentMethodPremiumsToBePaidInNextTwelveMonths	88039	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Two LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearTwo	100785	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Three LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearThree	78850	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Four LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFour	50388	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Five LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFive	32736	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid After Year Five LifeSettlementContractsInvestmentMethodPremiumsToBePaidAfterYearFive	366103	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Five Year Disclosure Premiums To Be Paid LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid	716901	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	470482	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25346	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	69762	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6729	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	400720	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18617	usd
CY2023	us-gaap	Depreciation Depreciation	63033	usd
CY2022	us-gaap	Depreciation Depreciation	4282	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	32900000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29300000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3364167	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	25935833	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3364167	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	6728333	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	5328333	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3911667	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3895000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2635000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	3437500	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	25935833	usd
CY2023Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	87297	usd
CY2021Q4	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	250000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	250000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Weighted Average Yield DebtSecuritiesAvailableForSaleWeightedAverageYield	0.06
CY2021Q4	abl	Debt Securities Available For Sale Equity Financing Threshold In Which Shares Convert DebtSecuritiesAvailableForSaleEquityFinancingThresholdInWhichSharesConvert	1000000	usd
CY2022Q4	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	500000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Weighted Average Yield DebtSecuritiesAvailableForSaleWeightedAverageYield	0.08
CY2022Q4	abl	Debt Securities Available For Sale Equity Financing Threshold In Which Shares Convert DebtSecuritiesAvailableForSaleEquityFinancingThresholdInWhichSharesConvert	5000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1105935	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	105935	usd
CY2023Q4	abl	Number Of Entities In Which Equity Securities Without Readily Determinable Fair Value Are Held NumberOfEntitiesInWhichEquitySecuritiesWithoutReadilyDeterminableFairValueAreHeld	2	entity
CY2023	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
CY2022	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1468535	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	889943	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-482139	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2023	us-gaap	Revenues Revenues	66401451	usd
CY2022	us-gaap	Revenues Revenues	44713552	usd
CY2023	us-gaap	Gross Profit GrossProfit	59911074	usd
CY2022	us-gaap	Gross Profit GrossProfit	38828883	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4905747	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2596140	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26482571	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1426865	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3409928	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4282	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-146443	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-347013	usd
CY2023	abl	Gain Loss On Change In Fair Value Of Warrant Liability GainLossOnChangeInFairValueOfWarrantLiability	-4204360	usd
CY2022	abl	Gain Loss On Change In Fair Value Of Warrant Liability GainLossOnChangeInFairValueOfWarrantLiability	0	usd
CY2023	us-gaap	Interest Expense InterestExpense	9866821	usd
CY2022	us-gaap	Interest Expense InterestExpense	42798	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	594764	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1474	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-2356058	usd
CY2022	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-90719	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	1369112	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1045623	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	704699	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	9516626	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	31682275	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1697178	usd
CY2022Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	8716111	usd
CY2023Q4	abl	Sensitivity Analysis Of Fair Value Life Settlement Contracts Fair Value Impact Of2 Percent Positive Change In Discount Rate SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate	111206993	usd
CY2023	abl	Sensitivity Analysis Of Fair Value Change In Life Settlement Contracts Fair Value Impact Of2 Percent Positive Change In Discount Rate SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate	-11089566	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	122296559	usd
CY2023Q4	abl	Sensitivity Analysis Of Fair Value Life Settlement Contracts Fair Value Impact Of2 Percent Adverse Change In Discount Rate SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate	130749053	usd
CY2023	abl	Sensitivity Analysis Of Fair Value Change In Life Settlement Contracts Fair Value Impact Of2 Percent Adverse Change In Discount Rate SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate	8452494	usd
CY2023	abl	Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets	-4028189	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome	944463	usd
CY2023	abl	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Equity Attributable To Noncontrolling Interest FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEquityAttributableToNoncontrollingInterest	303867	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-2356058	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	28249653	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-2356058	usd
CY2023	us-gaap	Fair Value Option Credit Risk Gains Losses On Assets FairValueOptionCreditRiskGainsLossesOnAssets	-1265103	usd
CY2023	abl	Fair Value Option Credit Risk Gains Losses On Assets Included In Equity Attributable To Noncontrolling Interest FairValueOptionCreditRiskGainsLossesOnAssetsIncludedInEquityAttributableToNoncontrollingInterest	-407028	usd
CY2023	abl	Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets	-4028189	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1831910	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	139820514	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	250000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	250000	usd
CY2022Q4	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	500000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1105935	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	105935	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1650000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1300000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	abl	Number Of Votes Per Common Share NumberOfVotesPerCommonShare	1	vote
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63388823	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63242173	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	146650	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50369350	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50369350	shares
CY2023Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	15000000	usd
CY2023Q4	us-gaap	Stock Repurchase Program Period In Force1 StockRepurchaseProgramPeriodInForce1	P18M
CY2023Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	13700000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	0	usd
CY2023	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	146650	shares
CY2023	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1283062	usd
CY2023Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	8.82
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	146650	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1283062	usd
CY2023Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	8.82
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	6.16
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.04
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	183439	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	22559	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1468535	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	889943	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.140
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.027
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	706686	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	195679	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	902365	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	469109	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	737376	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	97061	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	152567	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	566170	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	889943	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1468535	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	889943	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	2205635	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	6988538	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	2069993	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1414469	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2023	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	3812977	usd
CY2022	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	6147453	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-332567	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	174024	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-76018	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-125166	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1468535	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	889943	usd
CY2023Q4	abl	Deferred Tax Assets Life Settlement Contracts Sales DeferredTaxAssetsLifeSettlementContractsSales	1798639	usd
CY2022Q4	abl	Deferred Tax Assets Life Settlement Contracts Sales DeferredTaxAssetsLifeSettlementContractsSales	109902	usd
CY2023Q4	abl	Deferred Tax Assets Warrant Liabilities DeferredTaxAssetsWarrantLiabilities	1683658	usd
CY2022Q4	abl	Deferred Tax Assets Warrant Liabilities DeferredTaxAssetsWarrantLiabilities	0	usd
CY2023Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	740657	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	598274	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	usd
CY2023Q4	abl	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	455380	usd
CY2022Q4	abl	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	0	usd
CY2023Q4	abl	Deferred Tax Assets Debt DeferredTaxAssetsDebt	405804	usd
CY2022Q4	abl	Deferred Tax Assets Debt DeferredTaxAssetsDebt	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	264196	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21470	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	167554	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5703882	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	541652	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5703882	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	541652	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	7480659	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0	usd
CY2023Q4	abl	Deferred Tax Liabilities Life Settlement Contracts Change In Fair Value DeferredTaxLiabilitiesLifeSettlementContractsChangeInFairValue	4318194	usd
CY2022Q4	abl	Deferred Tax Liabilities Life Settlement Contracts Change In Fair Value DeferredTaxLiabilitiesLifeSettlementContractsChangeInFairValue	1454588	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	2398987	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	0	usd
CY2023Q4	abl	Deferred Tax Liabilities Change In Fair Value Of Debt DeferredTaxLiabilitiesChangeInFairValueOfDebt	0	usd
CY2022Q4	abl	Deferred Tax Liabilities Change In Fair Value Of Debt DeferredTaxLiabilitiesChangeInFairValueOfDebt	450884	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	705133	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14902973	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1905472	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	9199091	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1363820	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1893659	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	77011	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	118058	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	48127	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1796727	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29268	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1914785	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	77395	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	207508	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	48784	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	16103	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	3664	usd
CY2023	us-gaap	Lease Cost LeaseCost	223611	usd
CY2022	us-gaap	Lease Cost LeaseCost	52448	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	201200	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	48399	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1782726	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y3D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M29D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0967
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0336
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	118058	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	471239	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	485402	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	499980	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	514946	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	530391	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2620016	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	705231	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1914785	usd
CY2023	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	146650	shares
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	9516626	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	9516626	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	31682275	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	31682275	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56951414	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50369350	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	816484	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57767898	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50369350	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.17
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.63
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63

Files In Submission

Name	View Source	Status
0001814287-24-000028-index-headers.html	Edgar Link	pending
0001814287-24-000028-index.html	Edgar Link	pending
0001814287-24-000028.txt	Edgar Link	pending
0001814287-24-000028-xbrl.zip	Edgar Link	pending
abacuslifeincconsentgrantt.htm	Edgar Link	pending
abacuslifeincfs12312023311.htm	Edgar Link	pending
abacuslifeincfs12312023312.htm	Edgar Link	pending
abacuslifeincfs12312023321.htm	Edgar Link	pending
abacuslifeincfs12312023322.htm	Edgar Link	pending
abl-20231231.htm	Edgar Link	pending
abl-20231231.xsd	Edgar Link	pending
clawbackpolicy12312023.htm	Edgar Link	pending
descriptionofpubliclytrade.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
abl-20231231_cal.xml	Edgar Link	unprocessable
abl-20231231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abl-20231231_htm.xml	Edgar Link	completed
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R134.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
abl-20231231_lab.xml	Edgar Link	unprocessable
abl-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABL
Abacus Life, Inc. Stock $abl

2024 Q1 Form 10-K Financial Statement

#000181428724000028 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABL Abacus Life, Inc. Stock $abl

2024 Q1 Form 10-K Financial Statement

#000181428724000028 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABL
Abacus Life, Inc. Stock $abl